In a presentation at the Digital Biomarkers & Digital Measurements conference in 2022 about the clinical imperative of digital biomarkers, Dr. Arthur Combs, Senior Clinical Advisor to Activinsights, emphasizes the current need and opportunity to complete the clinical validation step of DiMe’s V3 Framework. He discusses how the V3 process answers how a biometric like step count can be endpoint specific in studies conducted in different therapeutic areas as he discussed earlier in his presentation.

Dr. Combs also notes that Activinsights has completed the first two steps of the V3 framework (technical and analytical validation) by characterizing the technology, algorithms, and capabilities for biometrics and, that now it’s time for the third step: finding the context of use.

Activinsights is a digital health company that specialises in the objective measurement of physical behaviours and lifestyle. Our technologies are used worldwide within the clinical trials, health management and research markets to provide accurate and continuous monitoring of lifestyle outside of the clinic environment.

"We have the technical capability, we now need to have the clinical focus and context of use to pursue digital biomarkers. That is what [the V3 framework] is about."

— Arthur Combs, MD, Senior Clinical Advisor, Activinsights